US FDA approves 2 Teva Pharmaceutical asthma inhalers
Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise
Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises
Essential IR Insights Newsletter - Summer July-August 2023
Insight Weekly: Climate law faces hurdles; US borrowing surges; banks revise uninsured deposits
The U.S. FDA approved two Teva Pharmaceutical Industries Ltd. asthma inhalers.
The inhalers, AirDuo RespiClick and ArmonAir RespiClick, will be available for adolescent and adult patients via prescription later this year.
